Advertisement

pp 1-14 | Cite as

Immunogenicity and Immunodominance in Antibody Responses

  • Monique Vogel
  • Martin F. BachmannEmail author
Chapter
Part of the Current Topics in Microbiology and Immunology book series

Abstract

A large number of vaccines exist that control many of the most important infectious diseases. Despite these successes, there remain many pathogens without effective prophylactic vaccines. Notwithstanding strong difference in the biology of these infectious agents, there exist common problems in vaccine design. Many infectious agents have highly variable surface antigens and/or unusually high antibody levels are required for protection. Such high variability may be addressed by using conserved epitopes and these are, however, usually difficult to display with the right conformation in an immunogenic fashion. Exceptionally high antibody titers may be achieved using life vectors or virus-like display of the epitopes. Hence, an important goal in modern vaccinology is to induce high antibody responses against fragile antigens.

References

  1. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitie MA, Sillman M, Savarese B, Mcneil JG, Macete E, Ballou WR, Cohen J, Alonso PL (2007) Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370(9598):1543–1551Google Scholar
  2. Bachmann MF, Hengartner H, Zinkernagel RM (1995) T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25(12):3445–3451Google Scholar
  3. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796Google Scholar
  4. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B cell responsiveness. Science 262(5138):1448–1451Google Scholar
  5. Bachmann MF, Zinkernagel RM (1996) The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 17(12):553–558Google Scholar
  6. Bachmann MF, Zinkernagel RM (1997) Neutralizing antiviral B cell responses. Annu Rev Immunol 15:235–270Google Scholar
  7. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF (2008) Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38(1):114–126Google Scholar
  8. Bessa J, Zabel F, Link A, Jegerlehner A, Hinton HJ, Schmitz N, Bauer M, Kündig TM, Saudan P, Bachmann MF (2012) Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A. 109(50):20566–20571Google Scholar
  9. Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, Von Der Borch P, Golic M, Moder S, Winter G, Coester C, Endres S (2008) Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 181(5):2990–2998Google Scholar
  10. Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M (2016) Sci Rep 19(6):19234Google Scholar
  11. Burton DR, Mascola JR (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16(6):571–576Google Scholar
  12. Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A, Bachmann M (2017) Microcrystalline Tyrosine (MCT®): a depot adjuvant in licensed allergy immunotherapy offers new opportunities in malaria. Vaccine 5(4)Google Scholar
  13. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, Van Melle G, Bangala Y, Guessous I, Muller P, Willers J, Maurer P, Bachmann MF, Cerny T (2008) A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3(6):e2547Google Scholar
  14. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A et al (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins. Science 333(6044):850–56.  https://doi.org/10.1126/science.1205669CrossRefGoogle Scholar
  15. Dintzis RZ, Vogelstein B, Dintzis HM (1982) Specific cellular stimulation in the primary immune response: experimental test of a quantized model. Proc Natl Acad Sci U S A 79(3):884–888Google Scholar
  16. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R et al (2012) Highly conserved protective epitopes on influenza B viruses. Science 337(6100):1343–48.  https://doi.org/10.1126/science.1222908CrossRefGoogle Scholar
  17. Eckl-Dorna J, Batista FD (2009) BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 113(17):3969–3977Google Scholar
  18. Eisenbarth SC, Colegio OR, O’connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198):1122–6Google Scholar
  19. Ekiert, DC, Bhabha G, Elsliger MA, Friesen RHE, Jongeneelen M, others (2009) Antibody Recognition of a Highly Conserved Influenza Virus Epitope. Science, 324.5924:246–51. http://dx.doi.org/10.1126/science.1171491
  20. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM (1996) Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157(2):541–548Google Scholar
  21. Gatto D, Pfister T, Jegerlehner A, Martin SW, Kopf M, Bachmann MF (2005) Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 201(6):993–1005Google Scholar
  22. Guevara Patino JA, Holder AA, Mcbride JS, Blackman MJ (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186(10):1689–1699Google Scholar
  23. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, Defranco AL (2011) Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34(3):375–384Google Scholar
  24. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF (2007) TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178(4):2415–2420Google Scholar
  25. Jegerlehner A, Schmitz N, Storni T, Bachmann MF (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172(9):5598–5605Google Scholar
  26. Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF (2002) Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32(11):3305–3314Google Scholar
  27. Jegerlehner A, Zabel F, Langer A, Dietmeier K, Jennings GT, Saudan P, Bachmann MF (2013) Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS ONE 8(11):e78947Google Scholar
  28. Jennings GT, Bachmann MF (2007) Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 7(2):143–155Google Scholar
  29. Justewicz DM, Doherty PC, Webster RG (1995) The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. J Virol 69(9):5414–5421Google Scholar
  30. Kang SM, Kim MC, Compans RW (2012) Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 11(8):995–1007Google Scholar
  31. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6(2):143–155Google Scholar
  32. Krammer F, Palese P, Steel J (2015) Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 386:301–321Google Scholar
  33. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF (2006) Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117(6):1470–1476Google Scholar
  34. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF (2012) Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 188(8):3724–3733Google Scholar
  35. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G (2011) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44):7826–7834Google Scholar
  36. Low JG, Lee LS, Ooi EE, Ethirajulu K, Yeo P, Matter A, Connolly JE, Skibinski DA, Saudan P, Bachmann M, Hanson BJ, Lu Q, Maurer-Stroh S, Lim S, Novotny-Diermayr V (2014) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine 32(39):5041–5048Google Scholar
  37. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38(5):1404–1413Google Scholar
  38. Matsushita M, Fujita T (2001) Ficolins and the lectin complement pathway. Immunol Rev 180:78–85Google Scholar
  39. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 8(9):992–1000Google Scholar
  40. Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, Selby MD, Brown AD, Coe JW, Badland M, Beal DM, Glen R, Wharton Y, Miller GJ, White P, Zhang N, Benoit M, Robertson K, Merson JR, Davis HL, Mccluskie MJ (2013) Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS ONE 8(10):e76557Google Scholar
  41. Rhee EG, Barouch DH (2009) Translational mini-review series on vaccines for HIV: harnessing innate immunity for HIV vaccine development. Clin Exp Immunol 157(2):174–180Google Scholar
  42. Sanders RW, Derking R, Cupo A, Julien J, Yasmeen A, De Val N, Kim HJ, Blattner C, De La Pena AT, Korzun J, Gobalek M, De Los Reyes K, Ketas T, Van Gils M, King C, Wilson I, Ward AB, Klasse P, Moore JP (2013) A next generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIp.664 gp140, expresses multiple epitopes for broadly neutralizing but non-neutralizing antibodies. PLos Pathog 9(9)(e1003618)Google Scholar
  43. Santiago FW, Lambert Emo K, Fitzgerald T, Treanor JJ, Topham DJ (2012) Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems. Vaccine 30(31):4606–4616Google Scholar
  44. Sattentau QJ (2014) Immunogen design to focus the B-cell repertoire. Curr Opin HIV AIDS 9(3):217–223Google Scholar
  45. Schiffner T, De Val N, Russell RA, De Taeye SW, De La Pena AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ (2016) Chemical cross-linking stabilizes native-like HIV-1 envelope glycoprotein trimer antigens. J Virol 90(2):813–828Google Scholar
  46. Schiller J, Chackerian B (2014) Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLos Pathog 10(8)(e1004254)Google Scholar
  47. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF (2012) Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 42(4):863–869Google Scholar
  48. Schodel F, Peterson D, Zheng J, Jones JE, Hughes JL, Milich DR (1993) Structure of hepatitis B virus core and e-antigen. A single precore amino acid prevents nucleocapsid assembly. J Biol Chem 268(2):1332–7Google Scholar
  49. Skibinski DA, Hanson BJ, Lin Y, Von Messling V, Jegerlehner A, Tee JB, De Chye H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE (2013) Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS ONE 8(10):e76571Google Scholar
  50. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM (2013) Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 31(40):4305–4313Google Scholar
  51. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM (2011) Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 108(2):757–761Google Scholar
  52. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A (2010) The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 40(3):638–642Google Scholar
  53. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172(3):1777–1785Google Scholar
  54. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3):265–273Google Scholar
  55. Thrane S, Janitzek CM, Matondo S, Resende M, GustavssonT, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte Bolmer M, van Gemert GJ, Sauerwein R, Schiller JT, NielsenMA, Theander TG, Salanti A, SanderAF (2016) J Nanobiotechnol (2016)14:30Google Scholar
  56. Thyagarajan R, Arunkumar N, Song W (2003) Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J Immunol 170(12):6099–6106Google Scholar
  57. Timmerman P, Puijk WC, Boshuizen RS, Van Dijken P, Slootstra JW, Beurskens FJ, Parren PWHI, Huber A, Bachmann MF, Meloen RH (2009) Functional Reconstruction of structurally complex epitopes using CLIPSTM technology. The Open Vaccine J 2:56–67Google Scholar
  58. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Muller P, Jennings GT, Wagner F, Bachmann MF (2008) Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371(9615):821–827Google Scholar
  59. Toapanta FR, Ross TM (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36(1–3):197–210Google Scholar
  60. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11(7):597–604Google Scholar
  61. Wyrzucki A, Bianchi M, Kohler I, Steck M, Hangartner L (2015) Heterosubtypic antibodies to influenza a virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies. J Virol 89.6 [Sandri-Goldin M (ed) American Society for Microbiology 3136–44] http://dx.doi.org/10.1128/JVI.03069-14
  62. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao HX, Cain DW, Spicer L, Vandeberg JL, Haynes BF, Kelsoe G (2013) Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210(2):241–256Google Scholar
  63. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M (2012) Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A 109(12):E690–E697Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Rheumatology, Immunology and AllergologyUniversity Hospital BernBernSwitzerland
  2. 2.The Jenner InstituteUniversity of OxfordOxfordUK

Personalised recommendations